Navigation Links
FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Date:6/20/2008

isturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions. Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy. Patients on oral antidiabetic medication while receiving VELCADE should check blood sugar levels frequently.

Adverse Reaction Data

Safety data from Phase II and III studies of single-agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with previously treated multiple myeloma (N=1008, not including the Phase III, VELCADE plus DOXIL(R) [doxorubicin HCl liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma.

In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), pain in limb and abdominal pain (each 15%), bone pain (14%), back pain and h
'/>"/>

SOURCE Millennium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Japan Approves CyberKnife System for Extracranial Use
2. FDA approves NeuRx diaphragm pacing system for use in spinal cord- injured patients
3. FDA Approves Cymbalta(R) for the Management of Fibromyalgia
4. ClearWay Minnesota(SM) Board Approves $1.4 Million in New Grants to Reduce Tobaccos Harm
5. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
6. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
7. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
8. FDA Approves Health Claim for Brown Rice
9. FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
10. FDA approves HeartMate II mechanical heart pump for heart-failure patients
11. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 An article ... problem which could prove critical to organizations that deal ... a critical aspect of data security, is worsening . ... data security report, every major category out of the ... penetration testing. “With all the craziness that has gone ...
(Date:3/28/2015)... 28, 2015 Delaying rotator cuff surgery ... according to research presented today at the American Orthopaedic ... , “Our study compared results for 170 patients who ... additional glenohumeral joint capsule release procedure to relieve stiffness ... PhD, lead author from St. George Hospital in Sydney, ...
(Date:3/28/2015)... Omaha, NE (PRWEB) March 28, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the Ohio Physical Therapy Association Annual ... the Renaissance Columbus Downtown Hotel in Columbus, OH. ... programming, networking opportunities, and exhibits with products and ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... receiving record amounts of money for such efforts , ... for tobacco prevention programs by more than 15 percent ... amounts of money from tobacco taxes and from the ... , "Fully funded tobacco prevention and cessation programs stop ...
... , , LANGHORNE, Pa., ... revolutionized with the introduction of TendoFlex - an innovative, ... motion exercises and abdominal core strengthening, allowing users to ... and aching. TendoFlex lets users stretch ...
... , , , HARROGATE, England, Dec. 9 ... on Polyphenols and Health (ICPH) further demonstrates that Concord grape ... function in certain population groups. The Concord grape has long ... healthy aging, and researchers are now also seeking to understand ...
... , ATLANTA and ... medical transcription service provider in the U.S. and the only leading ... been rated No. 1 in their category for professional services in ... report. A first-time entrant into the annual survey, ...
... , WINNIPEG, Manitoba, Dec. 9 IBM ... with the Government of Manitoba to enhance healthcare throughout the ... system. This technology can offer healthcare providers secure and quick ... and quality of patient care while reducing healthcare costs. ...
... Department of Neurology at Jefferson Medical College (JMC) of Thomas ... the National Institutes of Health (NIH) for the creation of ... science research to its translation into clinical applications. The ... as much as $10 million by the end of award ...
Cached Medicine News:Health News:States Slash Funding for Tobacco Prevention Programs 2Health News:States Slash Funding for Tobacco Prevention Programs 3Health News:All-New TendoFlex(TM) Revolutionizes Stretching and Core Strengthening 2Health News:The Concord Grape Commands Attention at Major Scientific Conference 2Health News:The Concord Grape Commands Attention at Major Scientific Conference 3Health News:The Concord Grape Commands Attention at Major Scientific Conference 4Health News:The Concord Grape Commands Attention at Major Scientific Conference 5Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 2Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 3Health News:IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care 2Health News:IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care 3
(Date:3/27/2015)... , March 27, 2015   Hospira, Inc. ... in biosimilars and the world,s leading provider of ... that support an evaluation of biosimilarity of its ... and Drug Administration (FDA) conditionally approved name of ... (epoetin alfa). These study data were presented at ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... specialty pharmaceutical and medical device company focused on ... primary and metastatic liver cancers, announces the reporting ... the Company,s Melphalan Hydrochloride for Injection with the ... therapies in a poster presentation at the Society of ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
Medicine Products: